Out-of-Pocket Healthcare Expenditure Burdens Among Nonelderly Adults With Hypertension | Page 3
Published Online: May 21, 2014
Didem Minbay Bernard, PhD; Patrik Johansson, MD, MPH; and Zhengyi Fang, MS
The increased prevalence of hypertension risk factors in the United States, in the form of an obesity epidemic and an aging population, underscores the importance of continued hypertension management and control. With the implementation of the Affordable Care Act (ACA), nonelderly adults with hypertension who are currently uninsured or have private non-group insurance will gain access to affordable coverage through the exchanges. Furthermore, the ACA sets limits on out-of-pocket spending for deductibles, coinsurance, and copayments. For the plan year beginning in 2014, the annual out-of-pocket maximums are $6350 for an individual and $12,700 for a family. Coverage through the exchanges and caps on outof- pocket spending are likely to reduce the prevalence of high burdens among adults with hypertension.
Hypertension represents the most common reason for office visits to primary care physicians.32-34 However, recent studies show that 80% of physicians are unaware of medication costs and also misunderstand the complexities of insurance coverage.35,36 Thus, raising awareness among providers regarding the prevalence of high out-of-pocket burdens and self-perceived financial barriers to care may encourage providers to discuss healthcare coverage and associated costs with their patients. To the extent that patients’ perceptions about their ability to pay are incorrect, physicians can change those perceptions. Furthermore, health plans could reduce patient cost sharing on drugs for which there is a strong body of evidence documenting cost-saving treatment such as antihypertensive medication. Addressing financial barriers to care may improve treatment adherence among patients with hypertension.
Author Affiliations: Agency for Healthcare Research and Quality— Center for Financing, Access and Cost Trends, Rockville, MD (DMB); University of Nebraska Medical Center, College of Public Health, Omaha, NE (PJ); Social & Scientific Systems, Silver Spring, MD (ZF).
Source of Funding: None reported.
Author Disclosures: The authors report no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this article.
Authorship Information: Concept and design (DMB, PJ); acquisition of data (DMB, ZF); analysis and interpretation of data (DMB, PJ, ZF); drafting of the manuscript (DMB, PJ); critical revision of the manuscript for important intellectual content (DMB); statistical analysis (ZF).
Address correspondence to: Didem Minbay Bernard, Agency for Healthcare Research and Quality, 540 Gaither Rd, Rockville, MD 20850. E-mail: Didem.Bernard@ahrq.hhs.gov.
1. Fields LE, Burt VL, Cutler JA, Hughes J, Roccella EJ, Sorlie P. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004;44(4):398-404.
2. Whitworth J. World Health Organization, International Society of Hypertension Writing Group, 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertension. 2003;21:1983-1992.
3. Xu J, Kochanek K, Murphy SL, et al. Deaths: final data for 2007. National Vital Statistics Reports. Centers for Disease Control and Prevention website. http://www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_19. pdf. Published May 20, 2010. Accessed January 16, 2012.
4. Heidenreich PA, Trogdon JG, Khavjou OA, et al. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-944.
5. Yoon S, Burt V, Louis T, Carroll M. Hypertension among adults in the United States, 2009-2010. National Center for Health Statistics Data Brief No. 107. Centers for Disease Control and Prevention website. http://www.cdc.gov/nchs/data/databriefs/db107.pdf. Published October 2012. Accessed January 16, 2012.
6. US Department of Health and Human Services. Healthy People 2020: heart disease and stroke objective 11. http://www.healthypeople.gov/ 2020/topicsobjectives2020/pdfs/HP2020objectives.pdf. Accessed January 16, 2012.
7. National high blood pressure education program. National Heart, Lung, and Blood Institute website. http://www.nhlbi.nih.gov/about/ nhbpep/nhbp_pd.htm. Accessed January 16, 2012.
8. US Department of Health and Human Services. About the National Quality Strategy (NQS). Agency for Healthcare Research & Quality website. http://www.ahrq.gov/workingforquality/about.htm. Accessed January 16, 2012.
9. Cutler DM, Long G, Berndt ER, et al. The value of antihypertensive drugs: a perspective on medical innovation. Health Aff (Millwood). 2007;26(1):97-110.
10. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42(6): 1206-1252.
11. Cutler JA, Sorlie PD, Wolz M, Thom T, Fields LE, Roccella EJ. Trends in hypertension prevalence, awareness, treatment, and control rates in United States adults between 1988-1994 and 1999-2004. Hypertension. 2008;52(5):818-827.
12. Chobanian AV. Impact of nonadherence to antihypertensive therapy. Circulation. 2009;120(16):1558-1560.
13. Ostchega Y, Yoon S, Hughes J, Louis T. Hypertension awareness, treatment, and control - continued disparities in adults: United States, 2005-2006. National Center for Health Statistics: NCHS Data Brief No 3. Centers for Disease Control and Prevention website. www.cdc.gov/ nchs/data/databriefs/db03.pdf. Published 2008.
14. Burnier M. Medication adherence and persistence as the cornerstone of effective antihypertensive therapy. Ame J Hypertens. 2006; 19(11):1190-1196.
15. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA. 2003;290:190-196.
16. Encinosa W, Bernard DM, Dor A. Does Prescription Drug Adherence Reduce Hospitalizations and Costs? The Case of Diabetes. Advances in Health Economics and Health Services Research. Volume 22, Pharmaceutical Markets and Insurance Worldwide. London: Emerald Group Publishing; 2010.
17. Rabbani A and Alexander GC. Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components. Am J Hypertens. 2008;21(5):509-513.
18. Ma J, Lee KV, Stafford RS. Changes in antihypertensive prescribing during US outpatient visits for uncomplicated hypertension between 1993 and 2004. Hypertension. 2006; 48:846-852.
19. Fischer MA and Avorn J. Economic Implications of evidence-based prescribing for hypertension: can better care cost less? JAMA. 2004; 291(15):1850-1856.
20. Matchar DB, McCrory DC, Orlando LA, et al. Comparative effectiveness of angiotesin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor antagonists (ARBs) for treating hypertension. Ann Intern Med. 2008;148(1):16-29.
21. Balu S, Thomas J 3rd. Incremental expenditure of treating hypertension in the United States. Am J Hypertens. 2006;19(8):810-816.
22. Cohen S. Sample Design of the 1997 Medical Expenditure Panel Survey Household Component, Methodology Report 11, AHRQ Pub. No. 01-0001 Rockville, MD: Agency for Healthcare Research and Quality.
23. Bernard DM, Farr S, Fang Z. National estimates of out-of-pocket health care expenditure burdens among nonelderly adults with cancer: 2001-2008. J Clin Oncol. 2011;29(20):2821-2826.
24. Bernard DM, Banthin JS, and Encinosa WE, Health care expenditure burdens among adults with diabetes in 2001. Med Care. 2006; 44:210-215.
25. Selden TM, Banthin JS. Health care expenditure burdens among elderly adults: 1987 and 1996. Med Care. 2003;41(7 suppl):III13-III23.
26. Banthin JS, Bernard DM. Changes in financial burdens for health care: national estimates for the population younger than 65 years, 1996 to 2003. JAMA. 2006;296(22):2712-2719.
27. Banthin JS, Cunningham P, Bernard DM, Financial burden of health care, 2001–2004. Health Aff. 2008;27(1):188-195.
28. Bernard DM, Banthin JS. Medicare Part D and health care expenditure burdens among the elderly: 2005 & 2007. AHRQ Working Paper. April 2010.
29. HCUP Clinical Classification Software. Healthcare Cost and Utilization Project (HCUP). Rockville, MD: Agency for Healthcare Research and Quality; January 2011.
30. Chronic condition indicator. Healthcare Cost and Utilization Project website. http://www.hcup-us.ahrq.gov/toolssoftware/chronic/chronic .jsp.
31. Bernard DM, Banthin JB, Encinosa WE. Wealth, income and the affordability of health insurance. Health Aff. 2009;28(3):887-896.
32. Elliott W. Improving outcomes in hypertensive patients: focus on adherence and persistence with hypertensive therapy. J Clin Hypertens. 2009;11:376-382.
33. Adherence to long term-therapies: evidence for action. World Health Organization website. www.who.int/chp/knowledge/ publications/adherence_report/en/.
34. US Department of Health and Human Services. National Ambulatory Medical Care Survey: 2006 summary. Centers for Disease Control and Prevention website. http://www.cdc.gov/nchs/data/nhsr/nhsr003 .pdf.
35. Morss SD, Klag MJ, Young JH. Is patients’ insurance coverage associated with prescribing after hospitalization for severe, poorly controlled hypertension? J Clin Hypertens. 2008;10(9):684-691.
36. Reichert S, Simon T, Halm EA. Physician’s attitudes about prescribing and knowledge of the costs of common medications. Arch Intern Med. 2000;160(18):2799-2803.